Kalvista Pharmaceuticals Stock Performance
| KALV Stock | USD 12.50 0.25 2.04% |
On a scale of 0 to 100, Kalvista Pharmaceuticals holds a performance score of 14. The company secures a Beta (Market Risk) of 1.33, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kalvista Pharmaceuticals will likely underperform. Please check Kalvista Pharmaceuticals' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Kalvista Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Kalvista Pharmaceuticals are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Kalvista Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.03 | Five Day Return 2 | Year To Date Return 38.26 | Ten Year Return (84.26) | All Time Return (84.26) |
Last Split Factor 1:14 | Dividend Date 2016-11-22 | Last Split Date 2016-11-22 |
1 | Insider Trading | 01/30/2025 |
2 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 11754 shares of Kalvista Pharmaceuticals at 8.89 subject to Rule 16b-3 | 02/03/2025 |
3 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 73649 shares of Kalvista Pharmaceuticals at 9.29 subject to Rule 16b-3 | 02/07/2025 |
4 | KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma Immunology 2025 Annual Meeting | 02/10/2025 |
5 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 26703 shares of Kalvista Pharmaceuticals at 9.18 subject to Rule 16b-3 | 02/11/2025 |
6 | Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 100000 shares of Kalvista Pharmaceuticals at 9.23 subject to Rule 16b-3 | 02/12/2025 |
7 | Disposition of 2419 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3 | 02/14/2025 |
8 | Disposition of 5104 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 9.8242 subject to Rule 16b-3 | 02/18/2025 |
9 | Acquisition by Christopher Yea of 4204 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 02/19/2025 |
10 | KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma Immunology 2025 Annual Meeting | 02/21/2025 |
11 | Disposition of 1918 shares by Christopher Yea of Kalvista Pharmaceuticals at 10.02 subject to Rule 16b-3 | 02/24/2025 |
12 | KalVista Pharmaceuticals, Inc. Insider Paul K. Audhya Sells 2,394 Shares of Stock | 02/26/2025 |
13 | KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma Immunology 2025 Annual Meeting | 03/03/2025 |
14 | Brokerages Set KalVista Pharmaceuticals, Inc. PT at 23.80 | 03/04/2025 |
15 | Disposition of 12084 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3 | 03/05/2025 |
16 | Disposition of 15625 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3 | 03/06/2025 |
17 | Disposition of 6669 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 11.97 subject to Rule 16b-3 | 03/07/2025 |
18 | KALVISTA PHARMACEUTICALS Earnings Results KALV Reports Quarterly Earnings - Nasdaq | 03/12/2025 |
19 | Acquisition by Benjamin Palleiko of 30195 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 03/14/2025 |
20 | Acquisition by Benjamin Palleiko of 9363 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 03/18/2025 |
21 | Technical Pivots with Risk Controls - Stock Traders Daily | 03/21/2025 |
| Begin Period Cash Flow | 56.2 M | |
| Free Cash Flow | -89.7 M |
Kalvista |
Kalvista Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 883.00 in Kalvista Pharmaceuticals on December 25, 2024 and sell it today you would earn a total of 335.00 from holding Kalvista Pharmaceuticals or generate 37.94% return on investment over 90 days. Kalvista Pharmaceuticals is currently generating 0.5877% in daily expected returns and assumes 3.2103% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Kalvista, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kalvista Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kalvista Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kalvista Pharmaceuticals, and traders can use it to determine the average amount a Kalvista Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1831
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KALV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.21 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.59 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Kalvista Pharmaceuticals is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kalvista Pharmaceuticals by adding it to a well-diversified portfolio.
Kalvista Pharmaceuticals Fundamentals Growth
Kalvista Stock prices reflect investors' perceptions of the future prospects and financial health of Kalvista Pharmaceuticals, and Kalvista Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kalvista Stock performance.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | 361.6 M | ||||
| Shares Outstanding | 49.72 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 4.20 X | ||||
| Price To Sales | 107.42 X | ||||
| Gross Profit | (81.07 M) | ||||
| EBITDA | (134.28 M) | ||||
| Net Income | (126.64 M) | ||||
| Cash And Equivalents | 142.08 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 7.32 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 17.51 X | ||||
| Book Value Per Share | 2.93 X | ||||
| Cash Flow From Operations | (89.23 M) | ||||
| Earnings Per Share | (3.77) X | ||||
| Market Capitalization | 609.02 M | ||||
| Total Asset | 235.4 M | ||||
| Retained Earnings | (469.73 M) | ||||
| Working Capital | 202.88 M | ||||
| Current Asset | 54.95 M | ||||
| Current Liabilities | 4.27 M | ||||
About Kalvista Pharmaceuticals Performance
Evaluating Kalvista Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Kalvista Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kalvista Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (9.33) | (8.87) | |
| Return On Tangible Assets | (1.09) | (1.03) | |
| Return On Capital Employed | 18.02 | 18.92 | |
| Return On Assets | (1.09) | (1.03) | |
| Return On Equity | 0.16 | 0.17 |
Things to note about Kalvista Pharmaceuticals performance evaluation
Checking the ongoing alerts about Kalvista Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kalvista Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kalvista Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (126.64 M) with loss before overhead, payroll, taxes, and interest of (81.07 M). | |
| Kalvista Pharmaceuticals currently holds about 142.08 M in cash with (89.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78. | |
| Kalvista Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Technical Pivots with Risk Controls - Stock Traders Daily |
- Analyzing Kalvista Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kalvista Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Kalvista Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kalvista Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kalvista Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kalvista Pharmaceuticals' stock. These opinions can provide insight into Kalvista Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.